Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TriSalus Life Sciences Inc. (TLSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TLSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $11.31
1 Year Target Price $11.31
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.6% | Avg. Invested days 64 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 206.97M USD | Price to earnings Ratio - | 1Y Target Price 11.31 |
Price to earnings Ratio - | 1Y Target Price 11.31 | ||
Volume (30-day avg) 8 | Beta 0.47 | 52 Weeks Range 3.50 - 6.04 | Updated Date 07/1/2025 |
52 Weeks Range 3.50 - 6.04 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -84.67% | Operating Margin (TTM) -79.95% |
Management Effectiveness
Return on Assets (TTM) -85.52% | Return on Equity (TTM) -496.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 226324675 | Price to Sales(TTM) 6.44 |
Enterprise Value 226324675 | Price to Sales(TTM) 6.44 | ||
Enterprise Value to Revenue 7.04 | Enterprise Value to EBITDA -5.96 | Shares Outstanding 37975800 | Shares Floating 29370602 |
Shares Outstanding 37975800 | Shares Floating 29370602 | ||
Percent Insiders 50.44 | Percent Institutions 8.11 |
Analyst Ratings
Rating 3 | Target Price 11.31 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences Inc. focuses on developing and commercializing technologies to treat liver and pancreatic tumors. The company was formerly known as Surefire Medical, Inc. and changed its name in July 2020. It went public through a SPAC merger in 2023.
Core Business Areas
- Drug-eluting System: TriSalus is dedicated to improving patient outcomes through the development of innovative delivery systems, particularly focused on regional cancer therapies.
- Pressure-Enabled Drug Delivery: Their core technology centers around pressure-enabled drug delivery to improve the penetration and efficacy of therapeutics in solid tumors of the liver and pancreas.
Leadership and Structure
The leadership team includes individuals with experience in medical device development and commercialization. The organizational structure reflects a focus on research and development, clinical trials, and commercial operations.
Top Products and Market Share
Key Offerings
- TriNav Infusion System: TriNav is their primary product, designed to deliver cancer therapeutics directly to liver tumors under pressure. Market share data is not widely published but the product competes with conventional TACE. Competitors: Boston Scientific, Cook Medical, Terumo.
- MATCH-ITSM Clinical Study: This study explores the use of TriNav in combination with immunotherapy for liver tumors. Early results suggest improved response rates. Competitors include researchers employing other drug delivery systems in combination with immunotherapies.
Market Dynamics
Industry Overview
The interventional oncology market is growing due to increasing cancer incidence and advancements in minimally invasive techniques. There is a strong need for more effective therapies for liver and pancreatic cancer.
Positioning
TriSalus positions itself as a leader in pressure-enabled drug delivery for liver and pancreatic tumors. Their competitive advantage lies in their proprietary technology and focus on regional therapy.
Total Addressable Market (TAM)
The TAM for liver and pancreatic cancer therapeutics is estimated to be several billion dollars annually. TriSalus is positioning themselves to capture a share of this market by addressing unmet needs in drug delivery.
Upturn SWOT Analysis
Strengths
- Proprietary pressure-enabled drug delivery technology
- Focus on difficult-to-treat liver and pancreatic tumors
- Potential for synergistic combination with immunotherapies
- Experienced leadership team
Weaknesses
- Limited commercial history as a public company
- Dependence on regulatory approvals for product expansion
- Potential for competition from established players
- Reliance on clinical trial outcomes
Opportunities
- Expansion into new indications and markets
- Partnerships with pharmaceutical companies
- Development of next-generation drug delivery systems
- Positive clinical trial results driving adoption
Threats
- Regulatory setbacks
- Competition from established medical device companies
- Negative clinical trial results
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- BSX
- COOK
- TRMO
Competitive Landscape
TriSalus is a smaller player in a market dominated by larger medical device companies. Its advantage is its novel technology, but it faces challenges in competing with the established sales and marketing infrastructure of its competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the recent public offering.
Future Projections: Future growth is expected to be driven by the adoption of TriNav and potential approvals of new products and indications. Analyst estimates vary.
Recent Initiatives: Recent initiatives include the ongoing MATCH-ITSM clinical study and efforts to expand the commercial reach of TriNav.
Summary
TriSalus Life Sciences Inc. is a promising company with a novel drug delivery technology focused on difficult-to-treat cancers. Its success depends on positive clinical trial results and successful commercialization efforts. The company faces competition from larger players and relies on regulatory approvals. Monitoring their financial performance and clinical development will be crucial in assessing their long-term viability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- TriSalus Life Sciences Inc. SEC Filings
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is based on available information and may not be precise. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-10 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 110 | Website https://trisaluslifesci.com |
Full time employees 110 | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.